{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T21:21:24Z","timestamp":1776892884979,"version":"3.51.2"},"reference-count":65,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clml.2024.01.003","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T01:39:21Z","timestamp":1704764361000},"page":"340-347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["SOHO State of the Art Updates and Next Questions | CTLs for Infections Following Stem Cell Transplantation"],"prefix":"10.1016","volume":"24","author":[{"given":"Ariel","family":"Rischall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clml.2024.01.003_bib0001","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3109\/07357907.2014.919301","article-title":"Complications of allogeneic hematopoietic stem cell transplantation","volume":"32","author":"Arnaout","year":"2014","journal-title":"Cancer Invest"},{"key":"10.1016\/j.clml.2024.01.003_bib0002","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3389\/fimmu.2017.01272","article-title":"Virus-specific T cells for the immunocompromised patient","volume":"8","author":"Houghtelin","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.clml.2024.01.003_bib0003","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/imr.12138","article-title":"Antiviral T-cell therapy","volume":"258","author":"Leen","year":"2014","journal-title":"Immunol Rev"},{"issue":"10","key":"10.1016\/j.clml.2024.01.003_bib0004","doi-asserted-by":"crossref","first-page":"e16547","DOI":"10.1172\/JCI165476","article-title":"Third party CMV viral specific T-cells for refractory CMV viremia and disease after hematopoietic transplant","volume":"133","author":"Prockop","year":"2023","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.clml.2024.01.003_bib0005","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood.V84.5.1689.1689","article-title":"Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation [letter]","volume":"84","author":"Hromas","year":"1994","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2024.01.003_bib0006","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199404283301703","article-title":"Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation","volume":"330","author":"Papadopoulou","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.01.003_bib0007","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1053\/bbmt.1999.v5.pm10465105","article-title":"Long term follow up of patients who achieved complete remission after donor leukocyte infusion","volume":"5","author":"Porter","year":"1999","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.clml.2024.01.003_bib0065","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/QCO.0000000000000456","article-title":"Infusion of cytotoxic T lymphocytes for the treatment of viral infections in hematopoetic stem cell transplant patients","volume":"31","author":"Baugh","year":"2018","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"10.1016\/j.clml.2024.01.003_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0701-1","article-title":"Strategies of adoptive T-cell transfer to treat refractory viral infections post allogeneic stem cell transplantation","volume":"12","author":"Kaeuferle","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"24","key":"10.1016\/j.clml.2024.01.003_bib0009","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1200\/JCO.20.02608","article-title":"Third-party BK virus-specific cytotoxic T lymphocyte therapy for hemorrhagic cystitis following allotransplantation","volume":"39","author":"Olson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.01.003_bib0010","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.01.003_bib0011","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.canlet.2015.08.007","article-title":"Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment","volume":"369","author":"Petrara","year":"2015","journal-title":"Cancer Lett"},{"issue":"11","key":"10.1016\/j.clml.2024.01.003_bib0012","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Duobrevina","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.01.003_bib0013","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","article-title":"Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation","volume":"31","author":"Icheva","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2024.01.003_bib0014","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/mt.2012.130","article-title":"Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections","volume":"20","author":"Gerdemann","year":"2012","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.clml.2024.01.003_bib0015","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.clml.2024.01.003_bib0016","first-page":"5","article-title":"Staging and response assessment in lymphomas: the new Lugano classification","volume":"4","author":"Cheson","year":"2015","journal-title":"Chin Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.01.003_bib0017","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2024.01.003_bib0018","doi-asserted-by":"crossref","first-page":"5476","DOI":"10.1182\/blood-2010-04-259291","article-title":"How I treat adenovirus in hematopoietic stem cell transplant recipients","volume":"116","author":"Lindemans","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2024.01.003_bib0063","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/TP.0b013e31823328c0","article-title":"BK virus-specific T cells for use in cellular therapy show specificity to multiple antigens and polyfunctional cytokine responses","volume":"92","author":"Blyth","year":"2011","journal-title":"Transplantation"},{"issue":"23","key":"10.1016\/j.clml.2024.01.003_bib0062","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","article-title":"How we treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.01.003_bib0019","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3389\/fimmu.2016.00352","article-title":"CMV-specific CD8 T cell differentiation and localization: implications for adoptive therapies","volume":"7","author":"Smith","year":"2016","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.clml.2024.01.003_bib0020","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbmt.2007.06.006","article-title":"Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources","volume":"13","author":"Walker","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.clml.2024.01.003_bib0021","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1182\/blood.V99.11.3916","article-title":"Infusion of cytomegalovirus (CMV)\u2013specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy","volume":"99","author":"Einsele","year":"2002","journal-title":"Blood"},{"issue":"9393","key":"10.1016\/j.clml.2024.01.003_bib0022","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(03)14634-X","article-title":"Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines","volume":"362","author":"Peggs","year":"2003","journal-title":"Lancet North Am Ed"},{"issue":"6","key":"10.1016\/j.clml.2024.01.003_bib0023","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbmt.2007.02.004","article-title":"Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Micklethwaite","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"10.1016\/j.clml.2024.01.003_bib0058","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","article-title":"Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation","volume":"116","author":"Feuchtinger","year":"2010","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clml.2024.01.003_bib0064","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.01.003_bib0024","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1182\/blood.V130.Suppl_1.747.747","article-title":"Adoptive T-cell therapy with 3rd party CMV-pp65-specific CTLs for CMV viremia and disease arising after allogeneic hematopoietic stem cell transplant","volume":"130","author":"Prockop","year":"2017","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2024.01.003_bib0025","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1182\/bloodadvances.2021004456","article-title":"Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted","volume":"5","author":"Rubinstein","year":"2021","journal-title":"Blood Adv"},{"issue":"31","key":"10.1016\/j.clml.2024.01.003_bib0026","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2024.01.003_bib0027","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jcyt.2015.07.005","article-title":"Addition of varicella zoster virus\u2013specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"17","author":"Ma","year":"2015","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.clml.2024.01.003_bib0028","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1078-0432.CCR-22-2415","article-title":"Posoleucel, an allogeneic, off-the-shelf multivirus-specific T-cell therapy, for the treatment of refractory viral infections in the post-HCT setting","volume":"29","author":"Pfeiffer","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.clml.2024.01.003_bib0029","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.bbmt.2014.10.012","article-title":"The effect of cidofovir on adenovirus plasma DNA levels in stem cell transplantation recipients without T cell reconstitution","volume":"21","author":"Lugthart","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"10.1016\/j.clml.2024.01.003_bib0030","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood-2016-11-749721","article-title":"Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant","volume":"129","author":"Hiwarkar","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2024.01.003_bib0031","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jcyt.2016.06.009","article-title":"Manufacture of GMP-compliant functional adenovirus-specific T-cell therapy for treatment of post-transplant infectious complications","volume":"18","author":"Horlock","year":"2016","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.clml.2024.01.003_bib0061","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/pbc.24753","article-title":"Adoptive immunotherapy with antigen-specific T cells during extracorporeal membrane oxygenation (ECMO) for adenovirus-related respiratory failure in a child given haploidentical stem cell transplantation","volume":"61","author":"Di Nardo","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"10.1016\/j.clml.2024.01.003_bib0059","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/bloodadvances.2019001120","article-title":"BK virus\u2013specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation","volume":"4","author":"Espada","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.clml.2024.01.003_bib0032","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/ajt.13635","article-title":"Symptomatic BK virus infection is associated with kidney function decline and poor overall survival in allogeneic hematopoietic stem cell recipients","volume":"16","author":"Abudayyeh","year":"2016","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.clml.2024.01.003_bib0057","doi-asserted-by":"crossref","first-page":"e13528","DOI":"10.1111\/ctr.13528","article-title":"BK polyomavirus in solid organ transplantation\u2014guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Hirsch","year":"2019","journal-title":"Clin Transplant"},{"issue":"5","key":"10.1016\/j.clml.2024.01.003_bib0033","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.1995.13.5.1103","article-title":"Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation","volume":"13","author":"Bedi","year":"1995","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.01.003_bib0034","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1756285615602832","article-title":"Progressive multifocal leukoencephalopathy: current treatment options and future perspectives","volume":"8","author":"Pavlovic","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"issue":"17","key":"10.1016\/j.clml.2024.01.003_bib0035","doi-asserted-by":"crossref","first-page":"11170","DOI":"10.1128\/JVI.79.17.11170-11178.2005","article-title":"Cross-reactivity of T lymphocytes recognizing a human cytotoxic T-lymphocyte epitope within BK and JC virus VP1 polypeptides","volume":"79","author":"Krymskaya","year":"2005","journal-title":"J Virol"},{"issue":"15","key":"10.1016\/j.clml.2024.01.003_bib0036","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMoa1801540","article-title":"Allogeneic BK virus\u2013specific T cells for progressive multifocal leukoencephalopathy","volume":"379","author":"Muftuoglu","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2024.01.003_bib0037","doi-asserted-by":"crossref","first-page":"116.e1","DOI":"10.1016\/j.jtct.2021.11.005","article-title":"Off-the-shelf third-party virus-specific T cell therapy to treat JC polyomavirus infection in hematopoietic stem cell transplantation recipients","volume":"28","author":"Jeremy","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.clml.2024.01.003_bib0038","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/s41422-021-00519-4","article-title":"SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target","volume":"31","author":"Xia","year":"2021","journal-title":"Cell Res"},{"issue":"9","key":"10.1016\/j.clml.2024.01.003_bib0039","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/cbin.11403","article-title":"Lymphopenia in COVID-19: therapeutic opportunities","volume":"44","author":"Fathi","year":"2020","journal-title":"Cell Biol Int"},{"issue":"7","key":"10.1016\/j.clml.2024.01.003_bib0066","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.cell.2020.10.049","article-title":"Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer","volume":"183","author":"Avanzato","year":"2020","journal-title":"Cell"},{"issue":"16","key":"10.1016\/j.clml.2024.01.003_bib0040","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.3390\/jcm10163595","article-title":"Severe lymphopenia as a predictor of COVID-19 mortality in immunosuppressed patients","volume":"10","author":"Mart\u00ednez-Urbistondo","year":"2021","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.clml.2024.01.003_bib0041","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.3324\/haematol.2022.281946","article-title":"Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high risk patients","volume":"108","author":"Vasileiou","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2024.01.003_bib67","unstructured":"Marin D. Viral Specific T Cell Therapy for COVID-19 Related Pneumonia. NCT04742595. Updated December 22, 2023. Accessed January 10, 2024. https:\/\/clinicaltrials.gov\/study\/NCT04742595."},{"issue":"3","key":"10.1016\/j.clml.2024.01.003_bib0042","doi-asserted-by":"crossref","first-page":"109432","DOI":"10.1016\/j.celrep.2021.109432","article-title":"Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy","volume":"36","author":"Basar","year":"2021","journal-title":"Cell Rep"},{"issue":"9080","key":"10.1016\/j.clml.2024.01.003_bib0043","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(97)03098-5","article-title":"Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia","volume":"350","author":"Hongeng","year":"1997","journal-title":"Lancet North Am Ed"},{"issue":"9","key":"10.1016\/j.clml.2024.01.003_bib0044","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1182\/bloodadvances.2021006309","article-title":"Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant","volume":"6","author":"Rubinstein","year":"2022","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.clml.2024.01.003_bib0045","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1182\/blood-2010-06-289991","article-title":"Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects","volume":"116","author":"Melenhorst","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.01.003_bib0046","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JCO.2012.43.5784","article-title":"Improving T-cell therapy for Epstein-Barr virus lymphoproliferative disorders","volume":"31","author":"Bollard","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.01.003_bib0047","first-page":"62","article-title":"The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation","volume":"3","author":"Barrett","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.clml.2024.01.003_bib0048","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.omtm.2017.02.001","article-title":"Toward a rapid production of multivirus-specific T cells targeting BKV, adenovirus, CMV, and EBV from umbilical cord blood","volume":"5","author":"Dave","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.clml.2024.01.003_bib0049","doi-asserted-by":"crossref","unstructured":"Lum L.G., Bollard C.M. Specific adoptive T-cell therapy for viral and fungal infections. Manag Infect Immunocompromised Host. 2018;395-411. Published 2018 Jun 19. doi:10.1007\/978-3-319-77674-3_20.","DOI":"10.1007\/978-3-319-77674-3_20"},{"issue":"1","key":"10.1016\/j.clml.2024.01.003_bib0053","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.seminhematol.2022.12.002","article-title":"Applications of virus-specific T cell therapies post-BMT","volume":"60","author":"Motta","year":"2023","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1016\/j.clml.2024.01.003_bib0054","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood.2021012249","article-title":"Cellular therapies for the treatment and prevention of SARS-CoV-2 infection","volume":"140","author":"Conway","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.01.003_bib0056","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2249.1996.tb08306.x","article-title":"Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes","volume":"103","author":"Lanza","year":"1996","journal-title":"Clin Experiment Immunol"},{"issue":"14","key":"10.1016\/j.clml.2024.01.003_bib0050","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1182\/bloodadvances.2020001977","article-title":"Large-scale GMP-compliant CRISPR-Cas9\u2013mediated deletion of the glucocorticoid receptor in multivirus-specific T cells","volume":"4","author":"Basar","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.01.003_bib0051","unstructured":"FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir\u2019sPosoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients. News release AlloVir. April 20:2022. https:\/\/ir.allovir.com\/news-releases\/news-release-details\/fda-grants-regenerative-medicine-advanced-therapy-rmat-0."},{"issue":"5","key":"10.1016\/j.clml.2024.01.003_bib0052","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/cid\/ciad233","article-title":"Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2\u2013Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients","volume":"77","author":"Haidar","year":"2023","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502400020X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502400020X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T13:02:15Z","timestamp":1716987735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502400020X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S215226502400020X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.01.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | CTLs for Infections Following Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}